These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15320474)

  • 21. The Pleiotropic Effects of Statins in Endocrine Disorders.
    De La Cruz JA; Mihos CG; Horvath SA; Santana O
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):787-793. PubMed ID: 30924424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleiotropic vascular protective effects of statins in perioperative medicine.
    Fang SY; Roan JN; Luo CY; Tsai YC; Lam CF
    Acta Anaesthesiol Taiwan; 2013 Sep; 51(3):120-6. PubMed ID: 24148741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins: potential new indications in inflammatory conditions.
    Endres M
    Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment].
    Iijima K; Ouchi Y
    Clin Calcium; 2010 Nov; 20(11):1719-28. PubMed ID: 21037393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Mason RP; Walter MF; Day CA; Jacob RF
    Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential benefit of statins for vascular disease in systemic sclerosis.
    Kuwana M
    Curr Opin Rheumatol; 2006 Nov; 18(6):594-600. PubMed ID: 17053504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins and blood pressure regulation.
    Borghi C; Veronesi M; Prandin MG; Dormi A; Ambrosioni E
    Curr Hypertens Rep; 2001 Aug; 3(4):281-8. PubMed ID: 11470010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic Effects of Statins on the Cardiovascular System.
    Oesterle A; Laufs U; Liao JK
    Circ Res; 2017 Jan; 120(1):229-243. PubMed ID: 28057795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent developments in the effects of nitric oxide-donating statins on cardiovascular disease through regulation of tetrahydrobiopterin and nitric oxide.
    Ma S; Ma CC
    Vascul Pharmacol; 2014 Nov; 63(2):63-70. PubMed ID: 25139660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pleiotropic effects of statins: do they matter?
    Gotto AM; Farmer JA
    Curr Opin Lipidol; 2001 Aug; 12(4):391-4. PubMed ID: 11507323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotropic effects and cholesterol-lowering therapy.
    Shaw SM; Fildes JE; Yonan N; Williams SG
    Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of statins on endothelium, inflammation and cardioprotection.
    Elrod JW; Lefer DJ
    Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy.
    Egom EE; Rose RA; Neyses L; Soran H; Cleland JG; Mamas MA
    Crit Rev Clin Lab Sci; 2013; 50(3):79-89. PubMed ID: 23885725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.